Robert J Bayer

USPTO Granted Patents = 37 (Patent Applications = 19)

CIPO Patents = 1

EPO Patents = 13 (Patent Applications = 13)

Average Co-Inventor Count = 4.6

ph-index = 25

Forward Citations = 1,387(Granted Patents)

Company Filing History:

18 out of 50

Neose Technologies, Inc.

Years Active: 1998-2014

Loading Chart...

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8911967 - One pot desialylation and glycopegylation of therapeutic peptides (2014-12-16),

2. 8853161 - Glycopegylation methods and proteins/peptides produced by the methods (2014-10-07),

3. 8791070 - Glycopegylated factor IX (2014-07-29),

4. 8716240 - Erythropoietin: remodeling and glycoconjugation of erythropoietin (2014-05-06),

5. 8716239 - Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF (2014-05-06),

6. 8633157 - Glycopegylated erythropoietin (2014-01-21),

7. 8632770 - Glycopegylated factor IX (2014-01-21),

8. 8404809 - Glycopegylated factor IX (2013-03-26),

9. 8076292 - Factor VIII: remodeling and glycoconjugation of factor VIII (2011-12-13),

10. 8063015 - Glycopegylation methods and proteins/peptides produced by the methods (2011-11-22),

11. 8008252 - Factor VII: remodeling and glycoconjugation of Factor VII (2011-08-30),

12. 7842661 - Glycopegylated erythropoietin formulations (2010-11-30),

13. 7795210 - Protein remodeling methods and proteins/peptides produced by the methods (2010-09-14),

14. 7696163 - Erythropoietin: remodeling and glycoconjugation of erythropoietin (2010-04-13),

15. 7569376 - Fucosyltransferase fusion protein (2009-08-04),

Title: Innovations and Contributions of Robert J Bayer in Therapeutic Peptides

Introduction: Robert J Bayer, based in San Diego, CA, has made significant strides in the field of biochemistry and pharmaceutical sciences. With a remarkable portfolio of 37 patents, Bayer has emerged as a leading inventor whose work enhances the development of therapeutic peptides.

Latest Patents: One of Robert J Bayer's notable patents involves "One pot desialylation and glycopegylation of therapeutic peptides." This invention focuses on creating conjugates between peptides and polyethylene glycol (PEG) moieties. These conjugates are linked through an intact glycosyl linking group that connects both the peptide and modifying group. The innovative approach allows for the ligation of a modified sugar moiety onto specific amino acids or glycosyl residues on the peptide, catalyzed by a glycosyltransferase. Furthermore, his patent covers pharmaceutical formulations that incorporate these conjugates and outlines methods for producing them. Another critical aspect of his work includes methodologies for remodeling peptide molecules through the addition or removal of glycosyl groups.

Career Highlights: Throughout his career, Robert J Bayer has held key positions at well-respected organizations such as Neose Technologies, Inc. and Novo Nordisk A/S. His experiences at these companies have helped shape his expertise in peptide therapeutics and contributed to his impressive record of patent filings.

Collaborations: Bayer has collaborated with several notable professionals in the industry, including Shawn DeFrees and David A Zopf. These partnerships have fostered a collaborative environment that has accelerated the innovation process in therapeutic peptide development.

Conclusion: Robert J Bayer's contributions to the field of therapeutic peptides are exemplified by his extensive patent portfolio and collaborative endeavors. His work not only advances scientific understanding but also significantly impacts the pharmaceutical industry by paving the way for new and effective treatments. As the landscape of biochemistry continues to evolve, Bayer's innovative spirit remains a valuable asset in the pursuit of healthcare improvements.

This text is generated by artificial intelligence and may not be accurate.